Cargando…

A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents

The alkylphosphocholine (APC) class of antineoplastic and antiprotozoal drugs, such as edelfosine and miltefosine, are structural mimics of lyso-phosphatidylcholine (lyso-PC), and are inhibitory to the yeast Saccharomyces cerevisiae at low micromolar concentrations. Cytotoxic effects related to inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Jaquelin M, Schwabe, Michael J, Voelker, Dennis R, Riekhof, Wayne R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496327/
https://www.ncbi.nlm.nih.gov/pubmed/34568930
http://dx.doi.org/10.1093/g3journal/jkab233
_version_ 1784579733866938368
author Garcia, Jaquelin M
Schwabe, Michael J
Voelker, Dennis R
Riekhof, Wayne R
author_facet Garcia, Jaquelin M
Schwabe, Michael J
Voelker, Dennis R
Riekhof, Wayne R
author_sort Garcia, Jaquelin M
collection PubMed
description The alkylphosphocholine (APC) class of antineoplastic and antiprotozoal drugs, such as edelfosine and miltefosine, are structural mimics of lyso-phosphatidylcholine (lyso-PC), and are inhibitory to the yeast Saccharomyces cerevisiae at low micromolar concentrations. Cytotoxic effects related to inhibition of phospholipid synthesis, induction of an unfolded protein response, inhibition of oxidative phosphorylation, and disruption of lipid rafts have been attributed to members of this drug class, however, the molecular mechanisms of action of these drugs remain incompletely understood. Cytostatic and cytotoxic effects of the APCs exhibit variability with regard to chemical structure, leading to differences in effectiveness against different organisms or cell types. We now report the comprehensive identification of S. cerevisiae titratable-essential gene and haploid nonessential gene deletion mutants that are resistant to the APC drug miltefosine (hexadecyl-O-phosphocholine). Fifty-eight strains out of ∼5600 tested displayed robust and reproducible resistance to miltefosine. This gene set was heavily enriched in functions associated with vesicular transport steps, especially those involving endocytosis and retrograde transport of endosome derived vesicles to the Golgi or vacuole, suggesting a role for these trafficking pathways in transport of miltefosine to potential sites of action in the endoplasmic reticulum and mitochondrion. In addition, we identified mutants with defects in phosphatidylinositol-4-phosphate synthesis (TetO::STT4) and hydrolysis (sac1Δ), an oxysterol binding protein homolog (osh2Δ), a number of ER-resident proteins, and multiple components of the eisosome. These findings suggest that ER-plasma membrane contact sites and retrograde vesicle transport are involved in the interorganelle transport of lyso-PtdCho and related lyso-phospholipid-like analogs to their intracellular sites of cytotoxic activity.
format Online
Article
Text
id pubmed-8496327
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84963272021-10-08 A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents Garcia, Jaquelin M Schwabe, Michael J Voelker, Dennis R Riekhof, Wayne R G3 (Bethesda) Mutant Screen Report The alkylphosphocholine (APC) class of antineoplastic and antiprotozoal drugs, such as edelfosine and miltefosine, are structural mimics of lyso-phosphatidylcholine (lyso-PC), and are inhibitory to the yeast Saccharomyces cerevisiae at low micromolar concentrations. Cytotoxic effects related to inhibition of phospholipid synthesis, induction of an unfolded protein response, inhibition of oxidative phosphorylation, and disruption of lipid rafts have been attributed to members of this drug class, however, the molecular mechanisms of action of these drugs remain incompletely understood. Cytostatic and cytotoxic effects of the APCs exhibit variability with regard to chemical structure, leading to differences in effectiveness against different organisms or cell types. We now report the comprehensive identification of S. cerevisiae titratable-essential gene and haploid nonessential gene deletion mutants that are resistant to the APC drug miltefosine (hexadecyl-O-phosphocholine). Fifty-eight strains out of ∼5600 tested displayed robust and reproducible resistance to miltefosine. This gene set was heavily enriched in functions associated with vesicular transport steps, especially those involving endocytosis and retrograde transport of endosome derived vesicles to the Golgi or vacuole, suggesting a role for these trafficking pathways in transport of miltefosine to potential sites of action in the endoplasmic reticulum and mitochondrion. In addition, we identified mutants with defects in phosphatidylinositol-4-phosphate synthesis (TetO::STT4) and hydrolysis (sac1Δ), an oxysterol binding protein homolog (osh2Δ), a number of ER-resident proteins, and multiple components of the eisosome. These findings suggest that ER-plasma membrane contact sites and retrograde vesicle transport are involved in the interorganelle transport of lyso-PtdCho and related lyso-phospholipid-like analogs to their intracellular sites of cytotoxic activity. Oxford University Press 2021-08-10 /pmc/articles/PMC8496327/ /pubmed/34568930 http://dx.doi.org/10.1093/g3journal/jkab233 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Genetics Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mutant Screen Report
Garcia, Jaquelin M
Schwabe, Michael J
Voelker, Dennis R
Riekhof, Wayne R
A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
title A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
title_full A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
title_fullStr A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
title_full_unstemmed A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
title_short A functional genomic screen in Saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
title_sort functional genomic screen in saccharomyces cerevisiae reveals divergent mechanisms of resistance to different alkylphosphocholine chemotherapeutic agents
topic Mutant Screen Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496327/
https://www.ncbi.nlm.nih.gov/pubmed/34568930
http://dx.doi.org/10.1093/g3journal/jkab233
work_keys_str_mv AT garciajaquelinm afunctionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT schwabemichaelj afunctionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT voelkerdennisr afunctionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT riekhofwayner afunctionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT garciajaquelinm functionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT schwabemichaelj functionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT voelkerdennisr functionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents
AT riekhofwayner functionalgenomicscreeninsaccharomycescerevisiaerevealsdivergentmechanismsofresistancetodifferentalkylphosphocholinechemotherapeuticagents